Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

OrlowskiR.

首页> 外文期刊>Cancer Cell >Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

【24h】

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

机译：为什么蛋白酶体抑制剂不能消除多发性骨髓瘤

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and colleagues describe XBP1s- subpopulations of tumor cells that are resistant to bortezomib and may account for therapeutic failures in the clinic.

机译：蛋白酶体抑制剂是我们对抗多发性骨髓瘤的武器库的关键组成部分，但该疾病可通过定义不明确的机制变得耐药。在本期《癌细胞》中，Leung-Hagesteijn及其同事描述了对硼替佐米具有抗药性且可能导致临床治疗失败的肿瘤细胞XBP1s亚群。

著录项

来源
《Cancer Cell》 |2013年第3期|共3页
作者
OrlowskiR.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma [J] . OrlowskiR. Cancer Cell . 2013,第3期

机译：为什么蛋白酶体抑制剂不能消除多发性骨髓瘤
2. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors [J] . Andrej Besse, Lenka Besse, Marianne Kraus, Cell chemical biology . 2019,第3期

机译：多种骨髓瘤中的蛋白酶体抑制：目前可用的蛋白酶体抑制剂的头部对比
3. Activating KRAS, NRAS, and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance [J] . Shirazi Fazal, Jones Richard J., Kuiatse Isere, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：激活KRA，NRA和BRAF突变体增强蛋白酶体能力并减少多发性骨髓瘤中的内质网胁迫，从而促进血浆细胞存活和蛋白酶体抑制剂
4. Controlled Release of Proteasome Inhibitor from Biodegradable Nanoparticles for Myeloma Therapies [C] . Gianni Rossini, Jack Trevino, Neal Vail Controlled Release Society Annual Meeting and Exposition . 2007

机译：蛋白酶体抑制剂从可降解纳米粒用于骨髓瘤治疗的控制释放。
5. The Role of Klf9 in Cell Stress-Induced Cell Death In Normal Cells and in the Therapeutic Response of Multiple Myeloma Cells to Proteasome Inhibitors [D] . Fink, Emily 2017

机译：Klf9在正常细胞中细胞应激诱导的细胞死亡中的作用以及在多发性骨髓瘤细胞对蛋白酶体抑制剂的治疗反应中的作用
6. Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma [O] . Robert Z. Orlowski -1

机译：为什么蛋白酶体抑制剂不能消除多发性骨髓瘤
7. Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma [O] . Orlowski Robert Z. 2013

机译：为什么蛋白酶体抑制剂不能消除多发性骨髓瘤

Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅